Nkarta, Inc. Common Stock (NKTX)
Nkarta, Inc. is a biotechnology company focused on developing allogeneic CAR NK (natural killer) cell therapies for cancer treatment. Leveraging its proprietary cell engineering platform, Nkarta aims to create off-the-shelf immunotherapies to improve efficacy and safety for patients with various cancers.
Company News
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.
Nkarta's stock surged 11.1% after Raymond James upgraded the stock to a strong buy, citing the company's strong cash position and the potential of its lead candidate NKX019 in treating autoimmune diseases.
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications. CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned trial in systemic lupus ...
Are these penny stocks a buy before next year? The post Penny Stocks To Buy Now? 4 To Watch Before 2024 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.